Nektar Therapeutics NKTR announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, ...

Shares of Exelixis, Inc. EXEL gained 7.4% on June 23, after the company announced positive top-line results from the ...

Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best biotech stocks to invest in now. On June 16, Gossamer Bio announced the ...

The results indicated that subjects who switched from alglucosidase alfa to cipa+mig generally achieved improvements or ...

College financing expert Mark Kantrowitz suggests that total borrowing should not exceed what a student expects to earn in ...

Shares of Nektar Therapeutics soared after the company said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin. The stock was up 31% at $12.49 in Monday's ...

Shares of BP rose Wednesday, lifted by a report that Shell was in talks to acquire it in what would mark a huge deal for the ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Hitting the primary endpoint on Compass Pathways plc’s Comp005 study of synthetic psilocybin, which the company billed as the first classic psychedelic to report phase III efficacy data, produced only ...

Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.

Shares of Summit Therapeutics SMMT tanked nearly 31% on Friday after it reported mixed results from the phase III HARMONi study, which evaluated its investigational antibody ivonescimab in certain ...